LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis pigmentosa.
Shares in the stem cell research company were up 22% at 320.00 pence each.
The company said latest results showed sustained and further improvement in vision at 60 and 120 days in first patient group of Phase 2a study of human retinal progenitor cell therapy in retinitis pigmentosa.
Subjects in the study showed a mean improvement from baseline in visual acuity of 23 letters in the treated eye. The untreated control eyes did not show meaningful improvement.
An improvement of 23 letters is equivalent to reading an additional four lines of letters on the eye chart. An improvement of at least 15 letters from baseline on the eye chart is considered to be clinically meaningful by the US Food & Drug Administration.
"The extent of vision improvement observed in this patient cohort demonstrates the potential for our hRPC cell therapy candidate to make an enormous difference in the lives of patients with RP. Treatment has already begun in the next cohort of patients, who have a greater baseline level of visual acuity than those treated so far. The results from this cohort will be presented in due course," ReNeuron Chief Executive Olav Hellebo said.
Reneuron (RENE)